NeuroSense Therapeutics (NASDAQ:NRSN) Stock Rating Cut to “Hold” at Roth Capital

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by Roth Capital from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.

NRSN has been the topic of several other research reports. Weiss Ratings downgraded shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. HC Wainwright assumed coverage on shares of NeuroSense Therapeutics in a research note on Thursday, September 3rd. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $170.00.

NeuroSense Therapeutics Stock Up 0.3%

Shares of NRSN opened at $3.49 on Monday. The company has a market cap of $6.63 million, a PE ratio of -0.32 and a beta of 1.66. The business has a fifty day moving average of $7.15 and a 200 day moving average of $12.11. NeuroSense Therapeutics has a 52-week low of $3.28 and a 52-week high of $26.64.

Institutional Investors Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned about 0.21% of NeuroSense Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is centered on therapeutic approaches intended to address multiple disease mechanisms, including neuroinflammation, abnormal RNA regulation and other biological processes associated with the progression of neurological disorders.

Its leading product candidate is PrimeC, an oral combination formulation of ciprofloxacin and celecoxib being developed primarily for amyotrophic lateral sclerosis (ALS).